published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsAman, 2021 0.51 [0.27; 0.96] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Shi, 2020 0.53 [0.01; 27.55] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Zhang, 2020 0.50 [0.17; 1.50] 0.73[0.58; 0.90]Aman, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Zhang, 20201315%3,672moderatelow death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsAman, 2021 0.51 [0.27; 0.96] CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] CAPE-COVID, 2020 0.45 [0.20; 1.02] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] Lopardo, 2021 0.57 [0.24; 1.37] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Shi, 2020 0.53 [0.01; 27.55] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Zhang, 2020 0.50 [0.17; 1.50] 0.75[0.62; 0.91]Aman, 2021, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Zhang, 20201816%4,813moderatelow deaths (time to event analysis only)detailed resultsCOVACTA (Rosas), 2020 1.16 [0.73; 1.84] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Zhang, 2020 0.50 [0.17; 1.50] 0.86[0.65; 1.14]COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Zhang, 2020731%2,853moderatenot evaluable clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] Zhang, 2020 0.87 [0.23; 3.27] 0.94[0.57; 1.55]CAP-China (Wang et al.), 2020, Zhang, 202020%293lownot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lopardo, 2021 1.61 [0.75; 3.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.09[0.96; 1.23]CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 20211013%2,814moderatecritical clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] Kalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.18[0.84; 1.66]CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021334%1,306moderatenot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] O’Donnell, 2021 1.38 [0.73; 2.61] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.35[1.04; 1.76]CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202160%1,023lowserious clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] 0.99[0.18; 5.51]CAP-China (Wang et al.), 202010%236NAnot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] 1.04[0.95; 1.14]CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 202070%2,483moderateserious death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] 0.76[0.49; 1.16]CAPE-COVID, 2020, Fragoso-Saavedra (PISCO), 2020, Rosas (REMDACTA), 2021347%986moderatenot evaluable hospital dischargedetailed resultsCAPE-COVID, 2020 1.67 [0.87; 3.19] Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] 1.04[0.90; 1.21]CAPE-COVID, 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Rosas (REMDACTA), 202140%1,200moderatenot evaluable mechanical ventilationdetailed resultsCAPE-COVID, 2020 0.95 [0.44; 2.04] COVACTA (Rosas), 2020 0.67 [0.39; 1.14] Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] 0.79[0.56; 1.11]CAPE-COVID, 2020, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, O’Donnell, 2021, PlasmAr, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202170%1,191moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] 0.81[0.27; 2.42]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] Lopardo, 2021 0.67 [0.35; 1.28] 0.57[0.36; 0.91]COVACTA (Rosas), 2020, Lopardo, 202120%432moderatenot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] 1.57[0.77; 3.20]COV-BARRIER (critically ill), 202210%101NAnot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Shi, 2020 1.08 [0.04; 32.96] 0.91[0.74; 1.11]CAP-China (Wang et al.), 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 202087%2,467moderatenot evaluable superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] 0.81[0.49; 1.34]CAPE-COVID, 202010%149NAnot evaluable adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Shi, 2020 0.88 [0.38; 2.03] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] 1.08[0.83; 1.39]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021713%1,707moderateserious deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] 0.36[0.13; 1.01]CAP-China (Wang et al.), 202010%233NAnot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] 1.09[0.42; 2.79]CAP-China (Wang et al.), 202010%233NAnot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] 1.01[0.03; 30.33]CAP-China (Wang et al.), 202010%233NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-10 00:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290